Teprotumumab treatment for dysthyroid optic neuropathy
All patients had CON improvement with teprotumumab, typically over a rapid time course, and the vast majority had CON resolution. Despite proptosis regression, nearly all patients remained CON-free at long-term follow-up. These results suggest that teprotumumab may be an effective treatment for dysthyroid optic neuropathy, especially for patients with mild CON.
Authors
- Suzanne K. Freitag (ORCID: https://orcid.org/0000-0003-0887-1487)
- Carolina A. Chiou (ORCID: https://orcid.org/0000-0002-0169-9429)
- Natalie Wolkow (ORCID: https://orcid.org/0000-0003-1524-115X)
- Tatiana R. Rosenblatt (ORCID: https://orcid.org/0000-0003-1694-405X)
- Darren A. Chen (ORCID: https://orcid.org/0000-0003-3096-7442)
- Michael K. Yoon (ORCID: https://orcid.org/0000-0002-8793-7685)
- Grace Lee (ORCID: https://orcid.org/0000-0001-7892-2871)
Institutions
- Massachusetts Eye and Ear Infirmary (US)
- Harvard University (US)
- Brown University (US)
- Broadlawns Medical Center (US)
Publication Details
- Journal
- Orbit
- Published
- 2025-11-05
- DOI
- https://doi.org/10.1080/01676830.2025.2578176
- Primary Topic
- Ophthalmology and Eye Disorders
- Type
- article
- Field-Weighted Citation Impact
- 0.00